As of March 31, 2026, Kolon TissueGene. Inc. Shs Korean Deposit Receipt Repr 1/5 Sh carries a market capitalization of 9.04T, placing it among publicly traded companies globally. Its enterprise value stands at 8.98T, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 9.04T |
| Enterprise Value | 8.98T |
As of March 31, 2026, Kolon TissueGene. Inc. Shs Korean Deposit Receipt Repr 1/5 Sh has 84.74M shares outstanding.
| Shares Outstanding | 84.74M |
These figures are as of March 31, 2026. The price-to-sales ratio is 1,649.97, and the price-to-book ratio stands at 72.43.
| PS Ratio | 1,649.97 |
| PB Ratio | 72.43 |
| P/TBV Ratio | -39.15 |
| P/FCF Ratio | -74.95 |
| P/OCF Ratio | -778.51 |
These figures are as of March 31, 2026. The EV/Sales ratio of 1,685.42 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 8.98T versus a market cap of 9.04T, with the gap driven by net debt and cash on the balance sheet.
| EV / Sales | 1,685.42 |
As of March 31, 2026, Kolon TissueGene. Inc. Shs Korean Deposit Receipt Repr 1/5 Sh maintains a current ratio of 0.33, meaning it holds 0.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 52.06, indicating elevated leverage, while an interest coverage ratio of -210.76 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.33 |
| Quick Ratio | 0.32 |
| Debt / Equity | 52.06 |
| Debt / EBITDA | -3.00 |
| Interest Coverage | -210.76 |
Over the twelve months ended March 31, 2026, Kolon TissueGene. Inc. Shs Korean Deposit Receipt Repr 1/5 Sh posted a negative return on equity (ROE) of -186.31, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -70.13, reflecting losses generated across the asset base. The company generates approximately 93.52M in revenue per employee across its workforce of 57.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 109.35 indicates how many times Kolon TissueGene. Inc. Shs Korean Deposit Receipt Repr 1/5 Sh sells and replaces its inventory over a year, a key working capital efficiency ratio.
| Return on Equity (ROE) | -186.31 |
| Return on Assets (ROA) | -70.13 |
| Revenue Per Employee | 93.52M |
| Employee Count | 57.00 |
| Inventory Turnover | 109.35 |
Over the twelve months ended March 31, 2026, Kolon TissueGene. Inc. Shs Korean Deposit Receipt Repr 1/5 Sh recorded 20.85M in income tax expense. The company reported a pretax loss of -287.38B and -287.40B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.
| Income Tax | 20.85M |
As of the close on November 17, 2026, Kolon TissueGene. Inc. Shs Korean Deposit Receipt Repr 1/5 Sh's stock has declined approximately 80.84% over the past 52 weeks. The 50-day moving average sits at 15,029.80, while the 200-day moving average is 66,618.75.
| 52-Week Price Change | -80.84% |
| 50-Day Moving Average | 15,029.80 |
| 200-Day Moving Average | 66,618.75 |
Over the twelve months ended March 31, 2026, Kolon TissueGene. Inc. Shs Korean Deposit Receipt Repr 1/5 Sh generated 5.33B in revenue and converted that into -287.40B in net income, yielding earnings per share of -3,486.64. EBITDA reached -21.64B, while operating income came in at -22.49B.
| Revenue | 5.33B |
| Gross Profit | 696.61M |
| Operating Income | -22.49B |
| Pretax Income | -287.38B |
| Net Income | -287.40B |
| EBITDA | -21.64B |
| EBIT | -22.49B |
| Earnings Per Share (EPS) | -3,486.64 |
As of March 31, 2026, Kolon TissueGene. Inc. Shs Korean Deposit Receipt Repr 1/5 Sh holds 122.09B in cash and equivalents against 64.99B in total debt, resulting in a net debt position of -35.29B. Total book value stands at 124.84B, with working capital of -254.45B providing operational flexibility.
| Cash & Cash Equivalents | 122.09B |
| Total Debt | 64.99B |
| Net Debt | -35.29B |
| Equity (Book Value) | 124.84B |
| Book Value Per Share | 1,473.24 |
| Working Capital | -254.45B |
Kolon TissueGene. Inc. Shs Korean Deposit Receipt Repr 1/5 Sh produced -11.30B in operating cash flow over the twelve months ended March 31, 2026. After subtracting -106.04B in capital expenditures, free cash flow totaled -117.34B - equivalent to -1,423.53 per share.
| Operating Cash Flow | -11.30B |
| Capital Expenditures | -106.04B |
| Free Cash Flow | -117.34B |
| FCF Per Share | -1,423.53 |
Over the twelve months ended March 31, 2026, Kolon TissueGene. Inc. Shs Korean Deposit Receipt Repr 1/5 Sh posted a gross margin of 13.07, reflecting its pricing power and cost economics. The operating margin of -421.91 and net profit margin of -5,391.61 provide insight into operational efficiency.
| Gross Margin | 13.07 |
| Operating Margin | -421.91 |
| Pretax Margin | -5,391.22 |
| Profit Margin | -5,391.61 |
| EBITDA Margin | -405.96 |
These figures cover the twelve months ended March 31, 2026. Free cash flow yield is negative at -1.33: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -2.00, meaning Kolon TissueGene. Inc. Shs Korean Deposit Receipt Repr 1/5 Sh raised more capital through share issuance and new debt than it returned via dividends and buybacks.
| Shareholder Yield | -2.00 |
| FCF Yield | -1.33 |
As of March 31, 2026, Kolon TissueGene. Inc. Shs Korean Deposit Receipt Repr 1/5 Sh has an Altman Z-Score of 4.75, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 4.75 |